Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Kalkine 0
countryflagAU

Probiotec Ltd

Healthcare AU PBP

NoneAUD
-(-%)

Last update at 2024-07-02T06:45:02.277343Z

Day Range

--
LowHigh

52 Week Range

2.082.99
LowHigh

Fundamentals

  • Previous Close 2.98
  • Market Cap242.34M
  • VolumeNone
  • P/E Ratio29.80
  • Dividend Yield2.35%
  • EBITDA27.21M
  • Revenue TTM221.22M
  • Revenue Per Share TTM2.72
  • Gross Profit TTM 64.34M
  • Diluted EPS TTM0.10

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax 15.57M 18.04M 7.72M 8.90M 4.99M
Minority interest - - - - -
Net income 11.02M 13.71M 4.85M 3.51M 3.51M
Selling general administrative 27.12M 14.77M 11.53M 0.53M 0.48M
Selling and marketing expenses 13.76M 11.45M 8.19M 7.96M 9.23M
Gross profit 64.34M 57.24M 38.70M 31.78M 25.75M
Reconciled depreciation 16.77M 14.77M 8.17M 5.31M 3.30M
Ebit 21.35M 22.32M 11.08M 11.19M 6.85M
Ebitda 38.12M 37.09M 19.26M 16.50M 10.14M
Depreciation and amortization 16.77M 14.77M 8.17M 5.31M 3.30M
Non operating income net other - - - - -
Operating income 20.73M 19.55M 11.02M 10.83M 6.85M
Other operating expenses 192.68M 160.01M 109.43M 96.03M 75.89M
Interest expense 5.77M 4.29M 3.36M 2.29M 1.85M
Tax provision 4.56M 4.33M 2.65M 2.46M 0.78M
Interest income - - - - -
Net interest income -5.77388M -4.28605M -3.36231M -2.29011M -1.85360M
Extraordinary items - 0.00000M -0.22319M -2.93588M 7.59M
Non recurring - - - - -
Other items - - - - -
Income tax expense 4.56M 4.33M 2.65M 2.46M 0.92M
Total revenue 214.03M 182.33M 120.51M 107.22M 79.09M
Total operating expenses 57.65M 50.02M 35.85M 26.26M 22.54M
Cost of revenue 149.69M 125.09M 81.81M 75.44M 53.35M
Total other income expense net 0.62M 2.77M 0.06M 0.36M -1.85360M
Discontinued operations - - -0.22319M -2.93588M 7.59M
Net income from continuing ops 11.02M 13.71M 5.07M 6.44M 4.07M
Net income applicable to common shares 11.02M 13.71M 4.85M 3.51M 11.33M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 235.44M 237.91M 230.88M 134.06M 106.37M
Intangible assets 20.16M 21.54M 21.88M 17.41M 9.25M
Earning assets - - - - -
Other current assets 1.44M 1.60M 0.99M 0.52M 6.21M
Total liab 148.30M 158.86M 162.26M 73.55M 56.52M
Total stockholder equity 87.14M 79.05M 68.61M 60.51M 49.85M
Deferred long term liab - - - - -
Other current liab 70.51M 4.21M 6.55M 11.34M 5.33M
Common stock 53.18M 51.29M 50.69M 43.74M 33.61M
Capital stock 53.18M 51.29M 50.69M 43.74M 33.61M
Retained earnings 33.31M 27.58M 17.85M 16.29M 15.65M
Other liab 19.27M 23.10M 27.98M 13.77M 11.09M
Good will 64.54M 64.54M 62.36M 25.54M 8.17M
Other assets 14.08M 14.99M 14.81M 8.33M 7.65M
Cash 14.05M 22.20M 28.43M 6.31M 8.84M
Cash and equivalents 14.05M 22.20M 28.43M 6.31M 8.84M
Total current liabilities 93.69M 51.43M 44.43M 25.65M 19.18M
Current deferred revenue -52.56187M 18.01M 17.24M -3.90028M -
Net debt 73.85M 70.79M 68.87M 31.72M 21.87M
Short term debt 52.56M 8.65M 7.44M 3.90M 4.47M
Short long term debt 46.96M 1.51M 1.56M 1.64M 1.84M
Short long term debt total 87.90M 92.99M 97.29M 38.02M 30.72M
Other stockholder equity 0.65M 0.18M 0.07M 0.48M 0.59M
Property plant equipment 60.99M 62.21M 64.05M 36.59M 34.23M
Total current assets 75.67M 74.63M 67.78M 46.19M 47.07M
Long term investments - - - - -
Net tangible assets 2.44M -7.02963M -15.62754M 17.56M 32.43M
Short term investments - - - - -
Net receivables 36.39M 31.23M 24.45M 22.94M 18.76M
Long term debt 0.00000M 46.96M 48.42M 9.66M 3.23M
Inventory 23.79M 19.60M 13.90M 15.70M 13.25M
Accounts payable 23.18M 20.55M 13.20M 14.32M 9.38M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.65M 0.18M 0.07M 0.48M 0.59M
Additional paid in capital - - - - -
Common stock total equity - - - 43.74M 33.61M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -145.68887M -148.29217M 0.00000M -79.54138M 16.40M
Deferred long term asset charges - - - - -
Non current assets total 159.77M 163.28M 163.10M 87.87M 59.30M
Capital lease obligations 40.94M 44.53M 47.32M 26.72M 25.65M
Long term debt total 35.33M 84.34M 89.86M 34.12M 26.25M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -13.73725M -16.47321M -35.85737M -24.95062M 30.06M
Change to liabilities 2.63M 9.16M -1.16567M 3.61M -3.41354M
Total cashflows from investing activities -13.73725M -16.47321M -35.85737M -24.95062M 30.06M
Net borrowings -6.66494M -5.89443M 37.38M 5.10M -8.59294M
Total cash from financing activities -11.58346M -9.27480M 33.61M 12.24M -18.64783M
Change to operating activities 1.06M -0.38592M -0.57039M 0.49M -0.66452M
Net income 11.02M 13.71M 4.85M 3.51M 4.07M
Change in cash -8.15315M -6.22319M 22.12M -2.53832M 7.03M
Begin period cash flow 22.20M 28.43M 6.31M 8.84M 1.82M
End period cash flow 14.05M 22.20M 28.43M 6.31M 8.84M
Total cash from operating activities 17.17M 19.52M 24.37M 10.17M -4.38532M
Issuance of capital stock 0.37M 0.60M - 10.14M 0.76M
Depreciation 13.08M 11.44M 7.68M 5.01M 3.30M
Other cashflows from investing activities -3.59363M -9.54035M -31.66873M -19.32009M 42.57M
Dividends paid 5.29M 3.98M 3.77M 2.99M 5.07M
Change to inventory -4.18860M -5.32651M 4.28M -0.38436M -1.69444M
Change to account receivables -5.15599M -6.77889M 7.69M -1.21182M -2.31022M
Sale purchase of stock 0.77M 6.47M -0.60000M -0.00871M -5.74307M
Other cashflows from financing activities -5.63812M -5.29443M 40.83M 8.52M 30.06M
Change to netincome 0.07M -2.31851M 0.04M -0.53788M -10.51889M
Capital expenditures 10.14M 6.93M 4.19M 5.63M 12.51M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -9.34458M -12.10540M 11.97M -1.59618M 0.15M
Stock based compensation 0.69M 0.45M 0.08M - -
Other non cash items -6.93348M -5.62235M 11.84M 3.26M -14.62651M
Free cash flow 7.02M 12.59M 20.18M 4.54M -12.51194M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PBP
Probiotec Ltd		 - -% - 29.80 - 1.06 2.64 1.39 8.58
AFP
AFT Pharmaceuticals Ltd		 - -% 2.46 25.00 21.60 1.26 2.90 1.44 13.74
VLS
Vita Life Sciences Ltd		 0.01 0.49% 2.06 12.88 - 1.43 2.17 1.08 6.36
SNT
Syntara Limited		 -0.01 14.93% 0.06 - 20.45 13.54 6.07 6.32 -2.1607
MVP
Medical Developments International		 -0.045 7.63% 0.55 - 166.67 1.69 1.21 1.35 278.77

Reports Covered

Stock Research & News

View All

Profile

Probiotec Limited engages in the development, manufacture, packing, distribution, and sale of prescription and over the counter pharmaceuticals, complementary medicines and consumer health products, and fast-moving consumer products in Australia and internationally. The company provides contract manufacturing services for solid dose tablets, capsules, and caplets; tablets coatings; blister packs, bottles, sachets, tubs, and tubes; liquids, creams, gels, lotions, ointments, and powders and powder blends. It is also involved in analytical and stability testing services; new product formulation and production trials, and ongoing research and development services; and packaging options for human and animal nutrition products, as well as manufactures and exports a range of nutraceuticals and functional ingredient raw materials. The company was incorporated in 1996 and is headquartered in Laverton North, Australia. As of June 18, 2024, Probiotec Limited operates as a subsidiary of PYFA Australia Pty Ltd.

Probiotec Ltd

83 Cherry Lane, Laverton North, VIC, Australia, 3026

Key Executives

Name Title Year Born
Mr. Wesley Stringer B.Comm, CPA, LLB (Hons) CEO, MD & Exec. Director NA
Mr. Jared Stringer B.Comm, BIT, CPA CFO, Company Sec. & Financial Controller NA
Ms. Julie McIntosh Chief Operating Officer NA
Mr. Alan Hong Gen. Mang. of Accounting NA
Mr. Dustin Stringer Gen. Mang. of Marketing NA
Ms. Annalinde Nickisch Chief People Officer NA
Ms. Jessica Walters Chief Customer Officer NA
Mr. Wesley Stringer B.Comm, CPA, LLB (Hons) CEO, MD & Executive Director NA
Mr. Jared Stringer B.Comm, BIT, CPA CFO, Company Secretary & Financial Controller NA
Mr. Alan Hong General Manager of Accounting NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.